265 related articles for article (PubMed ID: 33478189)
41. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
42. Advances in immunotherapy for non-small cell lung cancer.
Reckamp KL
Clin Adv Hematol Oncol; 2015 Dec; 13(12):847-53. PubMed ID: 27058851
[TBL] [Abstract][Full Text] [Related]
43. Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC.
Edlund K; Madjar K; Mattsson JSM; Djureinovic D; Lindskog C; Brunnström H; Koyi H; Brandén E; Jirström K; Pontén F; Rahnenführer J; Micke P; Hengstler JG
J Thorac Oncol; 2019 Apr; 14(4):628-640. PubMed ID: 30639618
[TBL] [Abstract][Full Text] [Related]
44. Immunotherapy in the treatment of non-small cell lung cancer.
Bílek O; Bořilová S; Grell P; Kiss I
Klin Onkol; 2021; 34(Supplementum 1):54-64. PubMed ID: 34154331
[TBL] [Abstract][Full Text] [Related]
45. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
[TBL] [Abstract][Full Text] [Related]
46. Principles of Immunotherapy in Non-Small Cell Lung Cancer.
Hsu ML; Naidoo J
Thorac Surg Clin; 2020 May; 30(2):187-198. PubMed ID: 32327177
[TBL] [Abstract][Full Text] [Related]
47. [Analysis of immune microenvironment by multiplex immunohistochemistry in locally advanced non-small cell lung cancer: Principles and perspectives].
Boulle G; Velut Y; Boni A; Lupo A; Alifano M; Trédaniel J; Giraud P; Damotte D
Cancer Radiother; 2018 Oct; 22(6-7):688-693. PubMed ID: 30131267
[TBL] [Abstract][Full Text] [Related]
48. Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity.
Rossi S; Castello A; Toschi L; Lopci E
Immunotherapy; 2018 Jul; 10(9):797-805. PubMed ID: 30008262
[TBL] [Abstract][Full Text] [Related]
49. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
50. Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
Bassanelli M; Sioletic S; Martini M; Giacinti S; Viterbo A; Staddon A; Liberati F; Ceribelli A
Anticancer Res; 2018 Jul; 38(7):3789-3796. PubMed ID: 29970498
[TBL] [Abstract][Full Text] [Related]
51. Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy.
Takamori S; Takada K; Shimokawa M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Takenoyama M; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
Int J Cancer; 2020 Oct; 147(8):2327-2334. PubMed ID: 32356560
[TBL] [Abstract][Full Text] [Related]
52. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
53. Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer.
Shukuya T; Carbone DP
J Thorac Oncol; 2016 Jul; 11(7):976-88. PubMed ID: 26944305
[TBL] [Abstract][Full Text] [Related]
54. Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives.
Guven DC; Sahin TK; Dizdar O; Kilickap S
Biomark Med; 2020 Oct; 14(14):1383-1392. PubMed ID: 33064030
[TBL] [Abstract][Full Text] [Related]
55. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
Suda K; Rozeboom L; Rivard CJ; Yu H; Ellison K; Melnick MAC; Hinz TK; Chan D; Heasley LE; Politi K; Mitsudomi T; Hirsch FR
Lung Cancer; 2017 Jul; 109():1-8. PubMed ID: 28577937
[TBL] [Abstract][Full Text] [Related]
56. Atezolizumab for the treatment of non-small cell lung cancer.
Santini FC; Rudin CM
Expert Rev Clin Pharmacol; 2017 Sep; 10(9):935-945. PubMed ID: 28714780
[TBL] [Abstract][Full Text] [Related]
57. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
58. The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.
Taube JM; Akturk G; Angelo M; Engle EL; Gnjatic S; Greenbaum S; Greenwald NF; Hedvat CV; Hollmann TJ; Juco J; Parra ER; Rebelatto MC; Rimm DL; Rodriguez-Canales J; Schalper KA; Stack EC; Ferreira CS; Korski K; Lako A; Rodig SJ; Schenck E; Steele KE; Surace MJ; Tetzlaff MT; von Loga K; Wistuba II; Bifulco CB;
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414858
[TBL] [Abstract][Full Text] [Related]
59. Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
Sun Z; Nyberg R; Wu Y; Bernard B; Redmond WL
PLoS One; 2021; 16(2):e0247238. PubMed ID: 33596250
[TBL] [Abstract][Full Text] [Related]
60. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
